Pharmaceutica Analytica Acta

Antibacterial activity of collagen/gelatin/Sodium alginate biomaterial with liposomes immobilized releasing antibiotics

International Conference on Bio-Pharmaceuticals, Biosimilars & Pharma Industry

February 28 - March 01, 2019 Osaka, Japan

Ming-Cheng Chang

Institute of Nuclear Energy Research, Taiwan

Scientific Tracks Abstracts: Pharm Anal Acta

Abstract:

Eye-drops therapy is the conventional dosage forms that account for 90% of currently accessible ophthalmic formulations. The major problem of eye-drops therapy encountered is rapid pre-corneal drug loss. Besides, high administration frequency seriously affected the quality of life of ophthalmological patients. In the current study, we developed a liposomal nanoparticle encapsulated with chloramphenicol mixed with biodegradable materials against ophthalmological disease. We first established the protocol for chloramphenicol loaded into liposomal nanoparticle; Liposomal chloramphenicol (LipoCAP). Then we established the collagen/gelatin/sodium alginate (CGA) as the component of biodegradable polymers and calibrated the novel drugs releasing formulation. Finally we combined LipoCAP with CGA to generate 8 hours-degradable ophthalmic chloramphenicol gel CGA-LipoCAP-8. Evidences indicated that CGA-LipoCAP-8 could reach the effective working concentration in 75 minutes and the drug releasing time could last for 12 hours. Besides, CGA-LipoCAP-8 could stably and continuously inhibit E. coli proliferation. The inhibiting phenomenon could be more pronounced with the time prolonging. Furthermore, there were no significant toxicities observed when CGA-LipoCAP-8 co-cultured with ocular epithelial cells. Our results of this proposal will provide innovative concepts and novel drugs releasing formulation for the future treatment of ophthalmological disease.

Recent Publications

1. Chang M C, Chen Y L et al. (2018) Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment. Molecular Therapy: The Journal of the American Society of Gene Therapy; 26: 404-419.

2. Chen Y L, Chang M C, Chiang Y C et al. (2018) Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Letters; 425: 152-163.

3. Chen Y L, Chang M C and Cheng W F (2017) Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Letters; 400: 282-292.

Biography :

Ming-Cheng Chang has his expertise in investigations in cancer vaccine and new therapeutic strategies development. He has generated several antigen-specific vaccines and combinational therapeutic strategies in treating gynecologic malignancy. He also built the novel dosage forms to prolong retention time in local area to improve the clinical application against infective illness. The foundation is based on the combination of liposome and bio-degradable matrix which is timecontrollable, rapid drug releasing and persistent format. These investigations could provide innovative concepts and novel drugs releasing formulation for the future treatment of ophthalmological disease.

E-mail: mcchang@iner.gov.tw